Appendix 3B - Proposed issue of securities Appendix 3B - Proposed issue of securities 1 / 5 Update Summary Entity name CAMBIUM BIO LIMITED Announcement Type Update to previous announcement Date of this announcement 2/9/2026 Reason for update to a previous announcement Correction to...
Update - Proposed issue of securities - CMB
Filed with ASX · · 5 pages · English
Release
Story so far
Earlier from Cambium Bio
- Notification regarding unquoted securities - CMB
- Proposed issue of securities - CMB
- FY26 Appendix 4E and Annual Report
- FY26 Appendix 4G and Corporate Governance Statement
- Change in Company Secretary and Communication Person
Later from Cambium Bio
- Change in Substantial Holding
- Notice of ceasing to be a substantial holder
- Cambium Bio Secures A$10.85 Million Funding Package
- Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease
- Notification of cessation of securities - CMB
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio